<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39400114</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1477-4054</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Briefings in bioinformatics</Title><ISOAbbreviation>Brief Bioinform</ISOAbbreviation></Journal><ArticleTitle>AntigenBoost: enhanced mRNA-based antigen expression through rational amino acid substitution.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">bbae468</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/bib/bbae468</ELocationID><Abstract><AbstractText>Messenger RNA (mRNA) vaccines represent a groundbreaking advancement in immunology and public health, particularly highlighted by their role in combating the COVID-19 pandemic. Optimizing mRNA-based antigen expression is a crucial focus in this emerging industry. We have developed a bioinformatics tool named AntigenBoost to address the challenge posed by destabilizing dipeptides that hinder ribosomal translation. AntigenBoost identifies these dipeptides within specific antigens and provides a range of potential amino acid substitution strategies using a two-dimensional scoring system. Through a combination of bioinformatics analysis and experimental validation, we significantly enhanced the in vitro expression of mRNA-derived Respiratory Syncytial Virus fusion glycoprotein and Influenza A Hemagglutinin antigen. Notably, a single amino acid substitution improved the immune response in mice, underscoring the effectiveness of AntigenBoost in mRNA vaccine design.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yumiao</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0008-0874-0085</Identifier><AffiliationInfo><Affiliation>NanoRibo (Shanghai) Biotechnology Co., Ltd., No. 1188 Lianhang Road, Minhang District, Shanghai 200003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Siran</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NanoRibo (Shanghai) Biotechnology Co., Ltd., No. 1188 Lianhang Road, Minhang District, Shanghai 200003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huichun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>NanoRibo (Shanghai) Biotechnology Co., Ltd., No. 1188 Lianhang Road, Minhang District, Shanghai 200003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Xueting</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>NanoRibo (Shanghai) Biotechnology Co., Ltd., No. 1188 Lianhang Road, Minhang District, Shanghai 200003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>NanoRibo (Shanghai) Biotechnology Co., Ltd., No. 1188 Lianhang Road, Minhang District, Shanghai 200003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Deng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>NanoRibo (Shanghai) Biotechnology Co., Ltd., No. 1188 Lianhang Road, Minhang District, Shanghai 200003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Zhikang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>NanoRibo (Shanghai) Biotechnology Co., Ltd., No. 1188 Lianhang Road, Minhang District, Shanghai 200003, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>NanoRibo (Shanghai) Biotechnology</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brief Bioinform</MedlineTA><NlmUniqueID>100912837</NlmUniqueID><ISSNLinking>1467-5463</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="Y">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="Y">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012136" MajorTopicYN="N">Respiratory Syncytial Viruses</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amino acid substitution</Keyword><Keyword MajorTopicYN="N">mRNA optimization</Keyword><Keyword MajorTopicYN="N">mRNA vaccine and therapeutics</Keyword><Keyword MajorTopicYN="N">nascent peptides</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39400114</ArticleId><ArticleId IdType="pmc">PMC11472322</ArticleId><ArticleId IdType="doi">10.1093/bib/bbae468</ArticleId><ArticleId IdType="pii">7820636</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gote V, Bolla PK, Kommineni N. et al. . A comprehensive review of mRNA vaccines. IJMS 2023;24:2700. 10.3390/ijms24032700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24032700</ArticleId><ArticleId IdType="pmc">PMC9917162</ArticleId><ArticleId IdType="pubmed">36769023</ArticleId></ArticleIdList></Reference><Reference><Citation>Poria R, Kala D, Nagraik R. et al. . Vaccine development: current trends and technologies. Life Sci 2024;336:122331. 10.1016/j.lfs.2023.122331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2023.122331</ArticleId><ArticleId IdType="pubmed">38070863</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeke R, Lentacker I, De Smedt SC. et al. . The dawn of mRNA vaccines: the COVID-19 case. J Control Release 2021;333:511–20. 10.1016/j.jconrel.2021.03.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2021.03.043</ArticleId><ArticleId IdType="pmc">PMC8008785</ArticleId><ArticleId IdType="pubmed">33798667</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics — developing a new class of drugs. Nat Rev Drug Discov 2014;13:759–80. 10.1038/nrd4278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4278</ArticleId><ArticleId IdType="pubmed">25233993</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X. Detailed dissection and critical evaluation of the Pfizer/BioNTech and Moderna mRNA vaccines. Vaccine 2021;9:734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8310186</ArticleId><ArticleId IdType="pubmed">34358150</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeke R, Lentacker I, Smedt SCD. et al. , Three decades of messenger RNA vaccine development. Nano Today 2019;28:100766.</Citation></Reference><Reference><Citation>Leppek K, Byeon GW, Kladwang W. et al. . Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat Commun 2022;13:1536. 10.1038/s41467-022-28776-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28776-w</ArticleId><ArticleId IdType="pmc">PMC8940940</ArticleId><ArticleId IdType="pubmed">35318324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson G. Codon optimality, bias and usage in translation and mRNA decay. Nature reviews Molecular cell biology 2018;19:20–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6594389</ArticleId><ArticleId IdType="pubmed">29018283</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspar P, Moura G, Santos MAS. et al. . mRNA secondary structure optimization using a correlated stem–loop prediction. Nucleic Acids Res 2013;41:e73–3. 10.1093/nar/gks1473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1473</ArticleId><ArticleId IdType="pmc">PMC3616703</ArticleId><ArticleId IdType="pubmed">23325845</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zhang L, Lin A. et al. . Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 2023;621:396–403. 10.1038/s41586-023-06127-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06127-z</ArticleId><ArticleId IdType="pmc">PMC10499610</ArticleId><ArticleId IdType="pubmed">37130545</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikita V, Shuhui L, Pooja G. et al. . mRNAid, an open-source platform for therapeutic mRNA design and optimization strategies. NAR Genomics and Bioinformatics 2024;6:lqae028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10935487</ArticleId><ArticleId IdType="pubmed">38482061</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Liang Y, Zhong X. et al. . Codon optimization with deep learning to enhance protein expression. Sci Rep 2020;10:17617. 10.1038/s41598-020-74091-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-74091-z</ArticleId><ArticleId IdType="pmc">PMC7572362</ArticleId><ArticleId IdType="pubmed">33077783</ArticleId></ArticleIdList></Reference><Reference><Citation>Şen A, Kargar K, Akgün E. et al. . Codon optimization: a mathematical programing approach. Bioinformatics 2020;36:4012–20. 10.1093/bioinformatics/btaa248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btaa248</ArticleId><ArticleId IdType="pubmed">32311016</ArticleId></ArticleIdList></Reference><Reference><Citation>McLellan JS, Chen M, Joyce MG. et al. . Structure-based Design of a Fusion Glycoprotein Vaccine for respiratory syncytial virus. Science 2013;342:592–8. 10.1126/science.1243283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1243283</ArticleId><ArticleId IdType="pmc">PMC4461862</ArticleId><ArticleId IdType="pubmed">24179220</ArticleId></ArticleIdList></Reference><Reference><Citation>Krarup A, Truan D, Furmanova-Hollenstein P. et al. . A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 2015;6:8143. 10.1038/ncomms9143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9143</ArticleId><ArticleId IdType="pmc">PMC4569726</ArticleId><ArticleId IdType="pubmed">26333350</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C-L, Goldsmith JA, Schaub JM. et al. . Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 2020;369:1501–5. 10.1126/science.abd0826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0826</ArticleId><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadani Y, Niwa T, Izumi T. et al. . Intrinsic ribosome destabilization underlies translation and provides an organism with a strategy of environmental sensing. Mol Cell 2017;68:528–539.e5. 10.1016/j.molcel.2017.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.10.020</ArticleId><ArticleId IdType="pubmed">29100053</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Chadani Y, Niwa T. et al. . Nascent peptide-induced translation discontinuation in eukaryotes impacts biased amino acid usage in proteomes. Nat Commun 2022;13:7451. 10.1038/s41467-022-35156-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35156-x</ArticleId><ArticleId IdType="pmc">PMC9718836</ArticleId><ArticleId IdType="pubmed">36460666</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke PC, Park H, Subramaniam AR. A nascent peptide code for translational control of mRNA stability in human cells. Nat Commun 2022;13:6829. 10.1038/s41467-022-34664-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34664-0</ArticleId><ArticleId IdType="pmc">PMC9652226</ArticleId><ArticleId IdType="pubmed">36369503</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan J, Britton PN, King CL. et al. . The immunogenicity and safety of respiratory syncytial virus vaccines in development: a systematic review. Influenza Resp Viruses 2021;15:539–51. 10.1111/irv.12850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12850</ArticleId><ArticleId IdType="pmc">PMC8189192</ArticleId><ArticleId IdType="pubmed">33764693</ArticleId></ArticleIdList></Reference><Reference><Citation>
US FDA approves GSK’s Arexvy . The world’s first respiratory syncytial virus (RSV) vaccine for older adults. London, UK:
GSK, 2023. https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/.</Citation></Reference><Reference><Citation>
US FDA approves expanded age indication for GSK’s Arexvy . The first respiratory syncytial virus (RSV) vaccine for adults aged 50–59 at Increased Risk. London, UK:
GSK, 2023. https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-expanded-age-indication-for-gsk-s-arexvy-the-first-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/#:∼:text=US%20FDA%20approves%20expanded%20age,59%20at%20increased%20risk%20%7C%20GSK.</Citation></Reference><Reference><Citation>Topalidou X, Kalergis AM, Papazisis G. Respiratory syncytial virus vaccines: a review of the candidates and the approved vaccines. Pathogens 2023;12:1259. 10.3390/pathogens12101259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens12101259</ArticleId><ArticleId IdType="pmc">PMC10609699</ArticleId><ArticleId IdType="pubmed">37887775</ArticleId></ArticleIdList></Reference><Reference><Citation>
U.S. FDA Approves ABRYSVO™ . Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults. United States:
Pfizer, 2023. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention.</Citation></Reference><Reference><Citation>
U.S. FDA Approves ABRYSVO™ . Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants through Active Immunization of Pregnant Individuals 32–36 Weeks of Gestational Age. United States:
Pfizer, 2023. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention-0.</Citation></Reference><Reference><Citation>Steff A-M, Monroe J, Friedrich K. et al. . Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV. Nat Commun 2017;8:1085. 10.1038/s41467-017-01092-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01092-4</ArticleId><ArticleId IdType="pmc">PMC5651886</ArticleId><ArticleId IdType="pubmed">29057917</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampmann B, Madhi SA, Munjal I. et al. . Bivalent Prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023;388:1451–64. 10.1056/NEJMoa2216480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2216480</ArticleId><ArticleId IdType="pubmed">37018474</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh EE, Pérez Marc G, Zareba AM. et al. . Efficacy and safety of a bivalent RSV Prefusion F vaccine in older adults. N Engl J Med 2023;388:1465–77. 10.1056/NEJMoa2213836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2213836</ArticleId><ArticleId IdType="pubmed">37018468</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson E, Goswami J, Baqui AH. et al. . Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med 2023;389:2233–44. 10.1056/NEJMoa2307079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2307079</ArticleId><ArticleId IdType="pubmed">38091530</ArticleId></ArticleIdList></Reference><Reference><Citation>
Moderna Receives U.S . FDA approval for RSV vaccine mRESVIA(R). United States: Moderna, 2024. https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx.</Citation></Reference><Reference><Citation>Joyce MG, Zhang B, Ou L. et al. . Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol 2016;23:811–20. 10.1038/nsmb.3267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.3267</ArticleId><ArticleId IdType="pmc">PMC5016229</ArticleId><ArticleId IdType="pubmed">27478931</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeseth AS, Cejas PJ, Citron MP. et al. . Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. npj Vaccines 2020;5:16. 10.1038/s41541-020-0163-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0163-z</ArticleId><ArticleId IdType="pmc">PMC7021756</ArticleId><ArticleId IdType="pubmed">32128257</ArticleId></ArticleIdList></Reference><Reference><Citation>Henikoff S, Henikoff JG. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci USA 1992;89:10915–9. 10.1073/pnas.89.22.10915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.22.10915</ArticleId><ArticleId IdType="pmc">PMC50453</ArticleId><ArticleId IdType="pubmed">1438297</ArticleId></ArticleIdList></Reference><Reference><Citation>Douka S, Brandenburg LE, Casadidio C. et al. . Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells. J Control Release 2023;361:455–69. 10.1016/j.jconrel.2023.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2023.08.014</ArticleId><ArticleId IdType="pubmed">37567506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y-P, Lei S-Y, Wang Y-B. et al. . Molecular evolution of attachment glycoprotein (G) and fusion protein (F) genes of respiratory syncytial virus ON1 and BA9 strains in Xiamen. China Microbiol Spectr 2022;10:e02083–21. 10.1128/spectrum.02083-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02083-21</ArticleId><ArticleId IdType="pmc">PMC9045328</ArticleId><ArticleId IdType="pubmed">35311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman MSA, Castellanos CA, Chen M. et al. . Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol 2016;1:eaaj1879. 10.1126/sciimmunol.aaj1879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aaj1879</ArticleId><ArticleId IdType="pmc">PMC5244814</ArticleId><ArticleId IdType="pubmed">28111638</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J, Evans R, Pritzel A. et al. . Highly accurate protein structure prediction with AlphaFold. Nature 2021;596:583–9. 10.1038/s41586-021-03819-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Muñoz ET, Deem MW. Epitope Analysis for Influenza Vaccine Design. Vaccine 2005;23:1144–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482133</ArticleId><ArticleId IdType="pubmed">15629357</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost SJ, Lee J, Gumina ME. et al. . Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site Following Vaccination of Humans. Cell Reports 2019;29:4460–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6953393</ArticleId><ArticleId IdType="pubmed">31875553</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C, Hou X, Yan J. et al. . Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens In vivo. Adv Mater 2020;32:e2004452. 10.1002/adma.202004452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202004452</ArticleId><ArticleId IdType="pmc">PMC8191860</ArticleId><ArticleId IdType="pubmed">32875709</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries O, Mc Cafferty S, De Smedt SC. et al. . N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release 2015;217:337–44. 10.1016/j.jconrel.2015.08.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.08.051</ArticleId><ArticleId IdType="pubmed">26342664</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M, Walls AC, Bowen JE. et al. . Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. Nat Struct Mol Biol 2020;27:942–9. 10.1038/s41594-020-0483-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-0483-8</ArticleId><ArticleId IdType="pmc">PMC7541350</ArticleId><ArticleId IdType="pubmed">32753755</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallesen J, Wang N, Corbett KS. et al. . Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA 2017;114:E7348–57. 10.1073/pnas.1707304114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1707304114</ArticleId><ArticleId IdType="pmc">PMC5584442</ArticleId><ArticleId IdType="pubmed">28807998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders RW, Derking R, Cupo A. et al. . A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013;9:e1003618. 10.1371/journal.ppat.1003618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003618</ArticleId><ArticleId IdType="pmc">PMC3777863</ArticleId><ArticleId IdType="pubmed">24068931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PS, Zhu X, Yu W. et al. . Design and structure of an engineered Disulfide-stabilized influenza virus hemagglutinin trimer. J Virol 2015;89:7417–20. 10.1128/JVI.00808-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00808-15</ArticleId><ArticleId IdType="pmc">PMC4473583</ArticleId><ArticleId IdType="pubmed">25926650</ArticleId></ArticleIdList></Reference><Reference><Citation>Impagliazzo A, Milder F, Kuipers H. et al. . A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015;349:1301–6. 10.1126/science.aac7263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac7263</ArticleId><ArticleId IdType="pubmed">26303961</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Deutsch C. Electrostatics in the ribosomal tunnel modulate chain elongation rates. J Mol Biol 2008;384:73–86. 10.1016/j.jmb.2008.08.089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2008.08.089</ArticleId><ArticleId IdType="pmc">PMC2655213</ArticleId><ArticleId IdType="pubmed">18822297</ArticleId></ArticleIdList></Reference><Reference><Citation>Charneski CA, Hurst LD. Positively charged residues are the major determinants of ribosomal velocity. PLoS Biol 2013;11:e1001508. 10.1371/journal.pbio.1001508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1001508</ArticleId><ArticleId IdType="pmc">PMC3595205</ArticleId><ArticleId IdType="pubmed">23554576</ArticleId></ArticleIdList></Reference><Reference><Citation>Po P, Delaney E, Gamper H. et al. . Effect of nascent peptide steric bulk on elongation kinetics in the ribosome exit tunnel. J Mol Biol 2017;429:1873–88. 10.1016/j.jmb.2017.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2017.04.019</ArticleId><ArticleId IdType="pmc">PMC5511029</ArticleId><ArticleId IdType="pubmed">28483649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman JM. The characterization of amino acid sequences in proteins by statistical methods. Journal of theoretical biology 1968;21:170–201.</Citation><ArticleIdList><ArticleId IdType="pubmed">5700434</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodríguez-Galán O, García-Gómez JJ, Rosado IV. et al. . A functional connection between translation elongation and protein folding at the ribosome exit tunnel in Saccharomyces cerevisiae. Nucleic Acids Res 2021;49:206–20. 10.1093/nar/gkaa1200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1200</ArticleId><ArticleId IdType="pmc">PMC7797049</ArticleId><ArticleId IdType="pubmed">33330942</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffat L, Jones DT. Increasing the accuracy of single sequence prediction methods using a deep semi-supervised learning framework. Bioinformatics 2021;37:3744–51. 10.1093/bioinformatics/btab491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btab491</ArticleId><ArticleId IdType="pmc">PMC8570780</ArticleId><ArticleId IdType="pubmed">34213528</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan DWA, Moffat L, Lau A. et al. . Deep learning for the PSIPRED protein analysis workbench. Nucleic Acids Res 2024;52:W287–93. 10.1093/nar/gkae328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkae328</ArticleId><ArticleId IdType="pmc">PMC11223827</ArticleId><ArticleId IdType="pubmed">38747351</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood TC. et al. , Evolution of protein sequences and structures. Journal of Molecular Biology 1999;291:977–95.</Citation><ArticleIdList><ArticleId IdType="pubmed">10452901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson CA, Kreychman J, Gerstein M. Assessing annotation transfer for genomics: quantifying the relations between protein sequence. Structure and Function through Traditional and Probabilistic Scores 2000;297:233–49.</Citation><ArticleIdList><ArticleId IdType="pubmed">10704319</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek M, DiMaio F, Anishchenko I. et al. . Accurate prediction of protein structures and interactions using a three-track neural network. Science 2021;373:871–6. 10.1126/science.abj8754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj8754</ArticleId><ArticleId IdType="pmc">PMC7612213</ArticleId><ArticleId IdType="pubmed">34282049</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald EF. Benchmarking AlphaFold2 on peptide structure prediction. Structure 2023;31:111–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9883802</ArticleId><ArticleId IdType="pubmed">36525975</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramson J, Adler J, Dunger J. et al. . Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 2024;630:493–500. 10.1038/s41586-024-07487-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07487-w</ArticleId><ArticleId IdType="pmc">PMC11168924</ArticleId><ArticleId IdType="pubmed">38718835</ArticleId></ArticleIdList></Reference><Reference><Citation>Guharoy M, Bhowmick P, Sallam M. et al. . Tripartite degrons confer diversity and specificity on regulated protein degradation in the ubiquitin-proteasome system. Nat Commun 2016;7:10239. 10.1038/ncomms10239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10239</ArticleId><ArticleId IdType="pmc">PMC4729826</ArticleId><ArticleId IdType="pubmed">26732515</ArticleId></ArticleIdList></Reference><Reference><Citation>Sora V, Laspiur AO, Degn K. et al. . RosettaDDGPrediction for high-throughput mutational scans: from stability to binding. Protein Sci 2023;32:e4527. 10.1002/pro.4527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.4527</ArticleId><ArticleId IdType="pmc">PMC9795540</ArticleId><ArticleId IdType="pubmed">36461907</ArticleId></ArticleIdList></Reference><Reference><Citation>Sample PJ, Wang B, Reid DW. et al. . Human 5′ UTR design and variant effect prediction from a massively parallel translation assay. Nat Biotechnol 2019;37:803–9. 10.1038/s41587-019-0164-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0164-5</ArticleId><ArticleId IdType="pmc">PMC7100133</ArticleId><ArticleId IdType="pubmed">31267113</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>